Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

Novartis AG (SWX: NOVN) has the cash to opt for a large deal in pursuit of accelerated growth – but it’s just not interested ...

Such companies can be wonderful options for income-seeking investments. If you're in the market for that combo, let's ...

UBS analyst Matthew Weston maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF111.00.Maximize ...

Day One Biopharma's OJEMDA FDA approval for pediatric glioma, but market concerns remain. Check out why I rate DAWN stock as ...

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis on Friday posted adjusted net income well above analyst estimates as sales of established heart failure drug ...

At prices below $100 per share, Novartis stock is an attractive buy, but investors need patience due to potential short-term revenue declines. With a dividend yielding nearly 3%, manageable debt ...

Vandana Singh Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases An Alphabet-backed startup is poised to ...